5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds

2. AbCellera Biologics Inc. (NASDAQ:ABCL)

Number of Hedge Fund Holders: 26

PE Ratio as of February 8: 13.52

AbCellera Biologics Inc. (NASDAQ:ABCL) is a Canadian biotech company that operates in the domain of human antibodies. AbCellera Biologics Inc. (NASDAQ:ABCL) has a PE ratio of 13.52 as of February 8. In December, AbCellera Biologics Inc. (NASDAQ:ABCL) rose after the company said it entered into a partnership with AbbVie (NYSE:ABBV) to discover antibody therapies. AbCellera Biologics Inc. (NASDAQ:ABCL)’s antibody discovery and development platform will be used to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications, according to the agreement.

Julian Baker and Felix Baker’s Baker Bros. Advisors was the biggest hedge fund stakeholder of AbCellera Biologics Inc. (NASDAQ:ABCL) at the end of the September quarter. The fund reported owning over 10 million shares of AbCellera Biologics Inc. (NASDAQ:ABCL), which had a net worth of about $103 million.